Table 1 Patient-reported outcomes collected in the Ig20Gly North American and European phase 2/3 trials

LQI^a

Treatment interference (scaled score range: 0–100)

• Interference with social/family life

• Time waiting

• Treatment is worthwhile

• Dependency on others

• Freedom to take trips or move

• Scheduled according to patient’s convenience

Scheduled according to patient’s convenience (score range: 1–7)

x

x

Therapy-related problems (scaled score range: 0–100)

• Convenience

• Painfulness

• Health improvement

• Anxiety or nervousness

Convenience (score range: 1–7)

x

x

Therapy setting (scaled score range: 0–100)

• Interference with work/school

• Given in a comfortable place

• Given in a pleasant atmosphere

Interference with work/school (score range: 1–7)

x

x

TSQM-9^b

Effectiveness (score range: 0–100)

• Ability of the medication to prevent or treat conditions

• The way the medication relieves symptoms

• Time before the medication works

–

x

–

Convenience (score range: 0–100)

• Easy/difficult to use the medication in its current form

• Easy/difficult to plan when to use the medication each time

• Convenient/inconvenient to take the medication as instructed

Convenient/inconvenient to take medication as instructed (score range: 1–7)

x

–

Global satisfaction (score range: 0–100)

• Overall confidence that taking this medication is a good thing

• Certainty that good things about medication outweigh bad things

• Overall satisfaction/dissatisfaction with medication

Overall satisfaction/dissatisfaction with medication (score range: 1–7)

x

–

Treatment preference^c

–

• Like/dislike aspects of administration

• Preference to continue Ig20Gly

Multiple items

–

x